systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-331Research ArticleКАРДИОЛОГИЯCARDIOLOGYПрактические аспекты применения фиксированных комбинаций в лечении артериальной гипертензииPractical aspects of fixed combinations in the treatment of hypertensionОгарковМ. Ю.OgarkovM. Yu.ogarmu@cardio.kem.ruБарановаМ. Н.BaranovaM. N.baranov1944@yandex.ruСкрипченкоА. Е.SkripchenkoA. E.scripae@cardio.kem.ruГБОУ ДПО Новокузнецкий государственный институт усовершенствования врачей Минздрава РоссииRussian FederationФГБУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний СО РАМНRussian Federation2014231220221112225Copyright © Огарков М.Ю., Баранова М.Н., Скрипченко А.Е., 20222022Огарков М.Ю., Баранова М.Н., Скрипченко А.Е.Ogarkov M.Y., Baranova M.N., Skripchenko A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/331

Артериальная гипертензия - ведущая причина возникновения инфарктов и инсультов. Достижение целевого уровня артериального давления (АД) при артериальной гипертензии является основным условием оптимизации прогноза в отношении сердечно - сосудистой заболеваемости и смертности. Для решения этой задачи значительная часть больных нуждаются в применении антигипертензивных препаратов, при этом у 70-80% целевой уровень АД может быть достигнут при использовании комбинированной терапии. Фиксированные комбинации антигипертензивных препаратов повышают приверженность пациентов лечению и обеспечивают лучшую органопротекцию. Новая фиксированная комбинация высокоселективного β-адреноблокатора бисопролола и антагониста кальция амлодипина позволяет достичь целевого уровня АД у 82,5% больных при минимальной частоте побочных эффектов.

Hypertension is a leading cause of heart attacks and strokes. Reaching target blood pressure (BP) in hypertension is the main condition optimization outlook for cardiovascular morbidity and mortality. To solve this problem in a substantial portion of patients, who are in need of antihypertensive drugs, wherein 70-80% of the target blood pressure can be achieved using a combination therapy. Fixed combinations of antihypertensive drugs increase treatment compliance and provide better organ protection. The new fixed combination of highly selective β-blocker bisoprolol and the calcium antagonist amlodipine can achieve target BP levels in 82,5% of patients with a minimum frequency of side effects.

артериальная гипертензиякомбинированная терапияфиксированные комбинациибисопрололамлодипинКонкор АМhypertensioncombination therapyfixed combinationsbisoprololamlodipineConcor AMReferencesОганов Р.Г., Тимофеева Т.Н., Колтунов И.Е. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003-2010 гг. Кардиоваск. терапия и профилактика. 2011; 1: 9-14.Оганов Р.Г., Тимофеева Т.Н., Колтунов И.Е. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003-2010 гг. Кардиоваск. терапия и профилактика. 2011; 1: 9-14.Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001; 2: 3-7.Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001; 2: 3-7.Здравоохранение в России. 2011. Статистический сборник. М.: Росстат, 2011.Здравоохранение в России. 2011. Статистический сборник. М.: Росстат, 2011.Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5-26.Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5-26.Hansson L, Zanchetti A, Carruthers S.G et al. Effect of intensive blood - pressure lowering and low - dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998; 351 (9118):1755-62.Hansson L, Zanchetti A, Carruthers S.G et al. Effect of intensive blood - pressure lowering and low - dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998; 351 (9118):1755-62.Cushman W.C, Ford C.E, Cutler J.A et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid - lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4 (6): 393-404.Cushman W.C, Ford C.E, Cutler J.A et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid - lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4 (6): 393-404.Dahlof B, Devereux R.B, Kjedsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trail against atenolol. Lancet 2002; 359 (9311): 995-1003.Dahlof B, Devereux R.B, Kjedsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trail against atenolol. Lancet 2002; 359 (9311): 995-1003.Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial Blood-Pressure- Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366 (9489): 895-906.Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial Blood-Pressure- Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366 (9489): 895-906.Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28 (12): 1462-536.Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28 (12): 1462-536.Law M.R, Wald N.J, Morris J.K, Jordan R.E. Value of low dose combination treatment with blood - pressure - lowering drugs: analysis of 354 randomized trials. BMJ 2003; 326 (7404): 1427.Law M.R, Wald N.J, Morris J.K, Jordan R.E. Value of low dose combination treatment with blood - pressure - lowering drugs: analysis of 354 randomized trials. BMJ 2003; 326 (7404): 1427.Gu Q, Dillon C, Burt V, Gillum R. Association of antihypertensive treatment and control with all - cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens 2010; 23: 38-45.Gu Q, Dillon C, Burt V, Gillum R. Association of antihypertensive treatment and control with all - cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens 2010; 23: 38-45.Singh B.N. Increased heart rate as a risk factor for cardiovascular disease. Eur Heart J Suppl 2003; 5 (Suppl. G): G3-G9.Singh B.N. Increased heart rate as a risk factor for cardiovascular disease. Eur Heart J Suppl 2003; 5 (Suppl. G): G3-G9.Palatini P et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313-21.Palatini P et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313-21.Asmar R.G, Kerihuel J.C, Girerd X.J, Safar M.E. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol 1991; 68 (1): 61-4.Asmar R.G, Kerihuel J.C, Girerd X.J, Safar M.E. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol 1991; 68 (1): 61-4.Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in non - asthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31 (2): 143-7.Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in non - asthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31 (2): 143-7.Broekman C.P, Yaensel S.M, van de Ven L.L, Slob A.K. Bisoprolol and hypertension; effects on sexual function in men. J Sex Marital Ther 1992; 18 (4): 325-31.Broekman C.P, Yaensel S.M, van de Ven L.L, Slob A.K. Bisoprolol and hypertension; effects on sexual function in men. J Sex Marital Ther 1992; 18 (4): 325-31.Frithz G. Effects of bisoprolol on blood pressure and serum lipids in the long - term treatment of essential hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 2): 424.Frithz G. Effects of bisoprolol on blood pressure and serum lipids in the long - term treatment of essential hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 2): 424.Janka H.U, Ziegler A.G, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin A1 in non - insulin - dependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S96-9.Janka H.U, Ziegler A.G, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin A1 in non - insulin - dependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S96-9.Buhler F.R, Berglund G, Anderson O.K et al. Double - blind of the cardioselective beta - blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 122-7.Buhler F.R, Berglund G, Anderson O.K et al. Double - blind of the cardioselective beta - blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 122-7.Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double - blind study (BISOMET). Eur Heart J 1987; 8 (Suppl. M): 103-13.Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double - blind study (BISOMET). Eur Heart J 1987; 8 (Suppl. M): 103-13.Goose P, Roudaut R, Herrero G, Dallocchio M. Beta - blockers vs. angiotensin - converting enzyme inhibitors in hypertension: effect on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5):145-50.Goose P, Roudaut R, Herrero G, Dallocchio M. Beta - blockers vs. angiotensin - converting enzyme inhibitors in hypertension: effect on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5):145-50.De Muinck E.D, Buchner-Moell D, van de Ven L.L, Lie K.I. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise - inducted angina pectoris: a Multicenter International Randomozed Study of Angina pectoris (MIRSA). J Cardiovasc Pharmacol 1992; 19 (6): 870-5.De Muinck E.D, Buchner-Moell D, van de Ven L.L, Lie K.I. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise - inducted angina pectoris: a Multicenter International Randomozed Study of Angina pectoris (MIRSA). J Cardiovasc Pharmacol 1992; 19 (6): 870-5.CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353 (9146): 9-13.CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353 (9146): 9-13.Golan D.E. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd ed. Philadelphia; London: Lippincott Williams & Wilkins 2008.Golan D.E. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd ed. Philadelphia; London: Lippincott Williams & Wilkins 2008.Dusing R. Optimizing blood pressure control through the use of fixed combination. Vasc Health Risc Manag 2010; 6: 321-5.Dusing R. Optimizing blood pressure control through the use of fixed combination. Vasc Health Risc Manag 2010; 6: 321-5.Blonde L, Wogen J, Kreilick C, Seymour A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co - administrated with metformin. Diabetes Obes Metab 2003; 5: 424-31.Blonde L, Wogen J, Kreilick C, Seymour A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co - administrated with metformin. Diabetes Obes Metab 2003; 5: 424-31.Gupta A, Arshad S, Poulter N. Compliance, safety and effectiveness of fixed - dose combinations of antihypertensive drugs: meta - analysis. Hypertension 2010; 55: 399-407.Gupta A, Arshad S, Poulter N. Compliance, safety and effectiveness of fixed - dose combinations of antihypertensive drugs: meta - analysis. Hypertension 2010; 55: 399-407.Rana R, Patil A. Efficacy and Safety of Bisoprolol plus Amlodipine Fixed Dose Combination in Essential Hypertension. The Indian Practitioner 2008; 61 (4): 225-34.Rana R, Patil A. Efficacy and Safety of Bisoprolol plus Amlodipine Fixed Dose Combination in Essential Hypertension. The Indian Practitioner 2008; 61 (4): 225-34.

The authors declare that there are no conflicts of interest present.